It’s no secret that traditional drug development is slow, expensive, not to mention risky, with nearly 90% of drug candidates failing to progress past clinical trials. But artificial intelligence (AI) is revolutionizing the process, delivering time and cost savings that were once unimaginable.

In recent years, AI has become integral to research and development strategies, and its influence is only accelerating. Industry experts estimate that AI adoption in the global drug discovery market will grow by 25–30% over the next five years.

And it’s already reshaping how research teams approach drug discovery across the R&D pipeline.

AI is enabling faster, smarter, and more cost-effective research, paving the way for breakthroughs that could transform healthcare. As AI adoption grows, the future of drug development will be shaped by how well organizations harness its power.

For many labs, that’s the conundrum: how and where to start harnessing AI’s power.  

Varya Virtual’s Iota is at the forefront of the AI revolution in the scientific world. Unlike other AI tools that focus on a single drug-discovery model, Iota’s power is in its flexible research infrastructure. By integrating seamlessly into research workflows, Iota accelerates target identification, streamlines candidate screening, and improves collaboration across teams. By capturing, organizing, and analyzing scientific data more efficiently, Iota reduces inefficiencies, cuts costs, and empowers organizations to achieve scientific breakthroughs.

The future of early drug discovery belongs to those who harness the power and potential of AI. Companies that embrace it will have a significant advantage over those that stick to traditional methods. AI-enabled platforms like Iota are helping organizations overcome bottlenecks and discover new levels of collaboration. The result will be a better pipeline: faster insights, fewer wasted experiments, and better decisions earlier in development. AI adoption is an ongoing process, with each step bringing greater connectivity and smarter decision-making to your lab bench.

Research labs worldwide recognize the critical importance of speed and efficiency. There’s much talk about artificial intelligence and its ability to accelerate scientific progress by automating repetitive tasks, analyzing large datasets, and providing timely insights. However, despite the appeal of AI, many labs remain hesitant to adopt it due to concerns about data security, reliability, and regulatory compliance.

And there’s good reason to pause.

While AI holds the potential to revolutionize how scientific discoveries reach the market, not all AI is the same. When labs use external AI tools outside of their control, they put their research at risk. That’s because third-party commercial tools like OpenClaw and ChatGPT (and others) can lead to issues like:

Why On-Premise AI Is Safer for Research Labs

So, how can research labs harness the power of AI without compromising data integrity or regulatory standards?

The answer lies in on-premise AI solutions like salAI.

salAI allows you to leverage AI’s benefits while keeping clinical data, batch records, intellectual property, and other proprietary information securely within your controlled network.

Here’s how:

While AI has the potential to revolutionize research operations, not all AI solutions are created equal. On-premise tools like salAI offer research labs the speed and automation benefits of AI with the added assurance of data privacy, traceability, and regulatory compliance. By choosing a secure, controlled AI environment, labs can confidently accelerate their discoveries without compromising on the integrity or security of their research.